首页> 外文期刊>Annals of surgical oncology >Body weight loss after surgery is an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer
【24h】

Body weight loss after surgery is an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer

机译:手术后体重减轻是继续进行胃癌S-1辅助化疗的独立危险因素

获取原文
获取原文并翻译 | 示例
       

摘要

Background: Compliance of S-1 adjuvant chemotherapy is not high. The aim of the present study is to clarify risk factors for continuation of S-1 after gastrectomy. Methods: This retrospective study selected patients who underwent curative D2 surgery for gastric cancer, were diagnosed with stage 2/3 disease, creatinine clearance more than 60 ml/min, and received adjuvant S-1 at our institution between June of 2002 and December of 2011. Time to S-1 treatment failure (TTF) was calculated. Results: A total of 103 patients were selected for the present study. When TTF curve stratified by each clinical factor was compared by the log-rank test, body weight loss (BWL) of 15 % was regarded as a critical point. Both univariate and multivariate Cox proportional hazard analyses demonstrated that BWL was the significant independent risk factor. Moreover, BWL remained a significant factor in both the univariate and multivariate analyses in the subset excluding 8 patients who discontinued S-1 because of recurrence. The 6-month continuation rate was 66.4 % in the patients with BWL < 15 and 36.4 % in patients with BWL ≥ 15 % (P =.017). Conclusions: BWL was the most important risk factor for the compliance of adjuvant chemotherapy with S-1 in the patients with stage 2/3 gastric cancer who underwent D2 gastrectomy. To improve drug compliance that leads to survival, it is a key to maintain body weight before starting S-1 adjuvant. Our study emphasizes the requirement for adequate studies of perioperative nutritional intervention in patients who receive gastrectomy for advanced gastric cancer.
机译:背景:S-1辅助化疗的依从性不高。本研究的目的是明确胃切除术后继续S-1的危险因素。方法:这项回顾性研究选择了2002年6月至2002年12月间在我院接受根治性D2手术治疗的胃癌,被确诊为2/3期疾病,肌酐清除率超过60 ml / min并接受佐剂S-1的患者。 2011年。计算出S-1治疗失败的时间(TTF)。结果:总共103名患者被选入本研究。当通过对数秩检验比较按每种临床因素分层的TTF曲线时,体重减轻(BWL)为15%被视为临界点。单因素和多因素Cox比例风险分析均表明BWL是重要的独立危险因素。此外,在排除8例因复发而中止S-1的患者中,BWL在单变量和多变量分析中仍然是一个重要因素。 BWL <15的患者的6个月持续率为66.4%,BWL≥15%的患者为66.4%(P = .017)。结论:BWL是2/3期胃癌行D2胃切除术的S-1辅助化疗依从性最重要的危险因素。为了提高药物依从性,从而导致生存,在开始使用S-1佐剂之前保持体重是关键。我们的研究强调对晚期胃癌接受胃切除术的患者围手术期营养干预进行充分研究的要求。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号